Indomethacin is the conventional medical treatment of patent ductus arteriosus (PDA) in preterms, inducing ductal closure in about 70% of the patients. To increase this success rate, it has been recommended to prolong the standard 3-dose course by an additional 3-dose course. Ibuprofen is as effective as indomethacin with less renal side effects. In order to determine if, like indomethacin, the effectiveness of ibuprofen is increased by a second course, we retrospectively looked at the data of 11 newborns (5 male/6 female, mean gestational age 26.9Ϯ1.8 weeks, mean birthweight 957Ϯ279 grams) who received 3 additional doses of ibuprofen after failure of the initial standard treatment. Standard ibuprofen treatment (10mg/kg, followed by 5 mg/kg twice at 24-hour intervals) was initiated at a mean age of 2.63Ϯ2.3 days in patients with symptomatic PDA on echocardiogram. Recurrence of a hemodynamically significant PDA warranted retreatment by 3 additional doses (same dose regimen). Five patients (nonresponders) still had a wide patent ductus at the end of the first course and received the second course immediately. The remaining six patients (responders) had either a closed or constricted PDA at the end of the first course but had to be retreated 10.4Ϯ5.7 (5-19) days later because of secondary relapse. Two patients had mild and transient renal failure during the first course, one of which experienced severe and prolonged renal failure after the second course. Eventually, 7/11 infants (4/5 nonresponders and 3/6 responders) required surgical ligation at a mean age of 22Ϯ10 days. In conclusion, when standard ibuprofen therapy fails to induce permanent ductus closure, a second course may avoid surgery in about one third of the patients. However, if standard ibuprofen therapy fails to initiate ductal constriction, the chances of success of a second course seem rather scarce and surgery may be more appropriate.
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PROTEIN INTAKE AFFECTS GLUCOSE METABOLISM PRIOR TO WEAN-ING IN RAT PUPS.

UNIVER-SITY OF UTAH, SALT LAKE CITY (USA)
Background: Fetal malnutrition can lead to a metabolic syndrome in adulthood. Early postnatal nutrition is probably also involved in metabolic programming. Epigenetic mechanisms could be responsible. Protein intake is frequently increased for small babies in order to attain catch-up growth. Short and long term effects of this practice at this critical period of life are not known.
Hypothesis: Protein overfeeding during the neonatal period could lead to modifications of glucose metabolism and epigenetic changes.
Methods: Rat pups were randomized in 3 experimental groups receiving different diets via gastrostomy with 50% (G50%), 100% (G100%) and 130% (G130%) of usual mother fed amount of protein from D7 to D15. The control group consisted of mother-fed pups (MF). At D15, the pups were sacrificed. Tissues were harvested for morphometry, epigenetic and biochemical analysis. Plasma insulin/glucose ratio was calculated. Epigenetic markers were studied in the brain: quantification of histone H3 acetylation and methylation, and of mRNA levels of the glucocorticoid receptors (GR).
Results: There was a trend toward higher insulin/glucose ratio in the G130%, and lower in the G50%.In G130% compared to G100% as control, H3/K14 acetylation increased (pϽ0.05). In contrast, H3/K9 acetylation decreased (pϽ0.01) and H3/K9 di-and trimethylation increased (pϽ0.01). mRNA levels of GR exon 1 isoforms 1.5 and 1.6 were decreased (pϽ0.01). Total body weight, liver and kidney weights did not differ among the groups, whereas brain weight per total body weight was greatest in the group fed 50% protein (pϽ0.005). There was no correlation between the pancreatic islet area and the insulin/glucose ratio.
Conclusion: These data suggest a trend toward glucose intolerance in infant rats receiving high protein diets, associated with epigenetic changes. Background: Fetal malnutrition can program for metabolic syndrome in adulthood. Postnatal nutrition probably also results in metabolic programming. Protein intakes for premature babies and newborns with IUGR are relatively high, in order to attain catch-up growth. Long term consequences of this high supply at this critical period of life are not known.
DOES PROTEIN INTAKE DURING INFANCY PROGRAM FOR GLUCOSE TOLERANCE IN ADULTHOOD?
Hypothesis: high protein intake during the preweaning period will result in long term metabolic consequences.
Methods: Rat pups were placed at birth in normal or expanded litters in order to create extra-uterine growth retardation. They were fed by gastrostomy from D7 to D15 and randomized into 3 groups with 50 %, 100% and 130% of usual mother fed amount of protein. Mother-fed pups (MF) served as reference controls. At D15, the pups were placed back with their mothers. Glucose tolerance tests were performed at D200. The weight was followed. Food consumption was also evaluated. The rats were sacrificed at D200 and the organs were harvested for morphometry and biochemical analyses.
Results: nϭ13 females in normal litter group, nϭ21 in litter expanded group. The weight of G50% was significantly less at D15, but not at D200. There was a trend to glucose intolerance with higher insulin/glucose ratio and basal insulin for G130% in the normal litter group, and in G130% and MF in the litter expanded group. The food consumption was not different among groups.
Conclusion: High protein intakes during infancy may lead to insulin resistance in adulthood. Catch-up diets may also lead to insulin resistance in adulthood. 
MEDICATION ERRORS ON THE NEONATAL UNIT
NEONATAL ICU, LIVERPOOL WOMENS HOSPITAL (UK)
Background: Medication errors are common in health care and have the potential to cause significant morbidity and mortality. There is little information regarding the nature, frequency and severity of such errors specifically in the neonatal population.
Aims/Objectives: To quantify (1) the frequency of medication errors, (2) identify the stage of the medication process where such errors occur and (3) describe the risk severity associated with each error.
Methods: All adverse clinical incidents and near-misses related to the medication process were identified from an Adverse Clinical Event (ACE) computer database during 2004. Errors were categorised by the stage of the medication process during which they occurred and the seriousness of risk posed. We also devised a new system of reporting where staff reported all medication errors anonymously. Reporting rates were compared with our traditional ACE reporting system to determine the extent of under-reporting of medication errors.
Results: A total of 505 ACEs were reported during the one year study period; of these, 109 (22%) were recorded as medication errors. The majority of medication errors were classified as near-miss events (89%) rather than adverse clinical incidents, and as low/very low risk (91%). Errors occurred most commonly in the ordering (34%) and administration (42%) steps of the medication process. Anonymous reporting led to 39 medication errors being highlighted during a one-week period (equivalent to 2028/year), suggesting that the true frequency of medication errors may be far higher than that identified by voluntary reporting through the ACE reporting system.
Conclusions: Medication errors are common in neonatal care, but most are near-misses rather than adverse clinical incidents. Ascertainment of such errors using a voluntary ACE reporting system is likely to result in a gross underestimate of the true error rate. We speculate that strategies that minimise ordering/administration errors may have the greatest impact in enhancing patient safety. 
